AMX0035 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease
Conditions
Alzheimer Disease
Trial Timeline
Sep 14, 2018 → Nov 6, 2020
NCT ID
NCT03533257About AMX0035 + Placebo
AMX0035 + Placebo is a phase 2 stage product being developed by Amylyx Pharmaceuticals for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03533257. Target conditions include Alzheimer Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533257 | Phase 2 | Completed |
Competing Products
20 competing products in Alzheimer Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 + Placebo | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| donanemab | Eli Lilly | Phase 2 | 52 |
| ATH-1017 | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 25 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 25 |